← Back to Search

Antiepileptic Drug

Keishibukuryogan for Epilepsy

Phase 2
Waitlist Available
Led By Timothy Welty, Pharm D
Research Sponsored by Timothy Welty, PharmD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 36 weeks

Summary

Epilepsy is a disorder in the brain. The brain is full of "nerve" cells. Nerve cells have normal electrical activity to control the many functions of the body. Sometimes nerve cells do not function normally due to many different reasons such as disease, an injury or because the brain didn't develop normally at birth. When nerve cells do not function normally the electrical activity that controls things like muscles and body movement can get mixed up and cause seizures. When a seizure occurs, sometimes a person loses control of body movement, and/or bodily functions. When a seizure occurs, a person may become unconscious, and/or senses may be affected. Seizures can occur at any time, without warning, and can lead to many health problems. "Catamenial epilepsy" is specific form of epilepsy in women. It is closely related to the menstrual cycle. In this form of epilepsy seizures increase around the menstrual period. By doing this study, researchers hope to learn whether Keishibukuryogan add-on therapy with antiepileptic drugs is safe for women with epilepsy.

Eligible Conditions
  • Epilepsy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 36 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 36 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To determine if Keishibukuryogan is safe for WWE
Secondary study objectives
To determine if KBG alters progesterone levels in WWE.
To determine if KBG changes seizure frequency in WWE, with a focus on increases in seizure frequency.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: KeishibukuryoganExperimental Treatment1 Intervention
Group II: AED treatment plus placeboActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Timothy Welty, PharmDLead Sponsor
Timothy Welty, Pharm DPrincipal InvestigatorUniversity of Kansas
~1 spots leftby Nov 2025